Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the expression of Y-box binding protein-1 (YB-1) in nonneoplastic cervical tissue and cervical cancer tissue and to evaluate its relationship with chemoradiosensitivity in the cases of cervical cancer. We performed immunohistochemical studies to examine YB-1 expression among 59 patients with cervical cancer, 30 with cervical intraepithelial neoplasia (CIN), and 30 with cervicitis. The mean YB-1 histological score(HSCORE)values for cervicitis, cervical CIN, and cervical cancer tissues were 22.3, 39, and 84.4, respectively. The mean YB-1 HSCORE value was 80.0 for cervical cancer patients who showed complete pathological response to chemoradiotherapy and 144.3 for cervical cancer patients who showed partial pathological response. Our data showed that the YB-1 expression was the highest in cervical cancer tissue, followed by cervical CIN tissue, and then cervicitis tissues. High YB-1 expression resulted in a lower pathological response rate in patients of cervical cancer than low YB-1 expression did. Our results implied that YB-1 may play a role in the genesis of cervical cancer and that high YB-1 expression decreases the chemoradiosensitivity of cervical cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.

    Article  PubMed  CAS  Google Scholar 

  3. Schoell WMJ, Janicek MR, Mirhashemi R. Epidemiology and biology of cervical cancer. Semin Surg Oncol. 1999;16:203–11.

    Article  PubMed  CAS  Google Scholar 

  4. Wan Fang, Miao X, Quraishi I, Kennedy V, Kim E, Creek KE, Pirisi L. Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer. 2008;123:32–40.

    Article  PubMed  CAS  Google Scholar 

  5. Narisawa-Saito M, Yoshimatsu Y, Ohno S, Yugawa T, Egawa N, Fujita M, Hirohashi S, Kiyono T. An in vitro multistep carcinogenesis model for human cervical cancer. Cancer Res. 2008;68:5699–705.

    Article  PubMed  CAS  Google Scholar 

  6. Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007;335:765–8.

    Article  PubMed  Google Scholar 

  7. Poujade O, Morice P, Rouzier R, Madelenat P, Lecuru F, Muray JM, Mathevet P, Alran S, Salmon RJ, Reyal F. Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study. Int J Gynecol Cancer. 2010;20:815–20.

    Article  PubMed  Google Scholar 

  8. Zhu H, Pei HP, Zeng S, Chen J, Shen LF, Zhong MZ, Yao RJ, Shen H. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res. 2009;8:3969–76.

    Article  PubMed  CAS  Google Scholar 

  9. Tanaka T, Bai T, Yukawa K, Utsunomiya T, Umesaki N. Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. Oncol Rep. 2005;14:941–8.

    PubMed  CAS  Google Scholar 

  10. Gu C, Oyama T, Osaki T, Kohno K, Yasumoto K. Expression of Y box-binding protein 1 correlates with DNA topoisomerase II alpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res. 2001;21:2357–62.

    PubMed  CAS  Google Scholar 

  11. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151–5.

    PubMed  CAS  Google Scholar 

  12. Faury D, Nantel A, Dunn SE, Guiot M-C, Haque T, Hauser P, Garami M, Bognár L, Hanzély Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret A-S, Del Maestro RF, Gleave M, Montes J-L, Pietsch T, Albrecht S, Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25:1196–208.

    Article  PubMed  CAS  Google Scholar 

  13. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TPH, Lam W, Pugh T, Marra MA, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. Breast Cancer Res. 2007;9:R61.

    Article  PubMed  Google Scholar 

  14. Wu J, Lee C, Yokom D, Jiang H, Cheang MCU, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks B, Dunn SE. Disruption of the Y-box binding protein-1 (YB-1) results in suppression of the epidermal growth factor receptor and Her-2. Cancer Res. 2006;66:4872–9.

    Article  PubMed  CAS  Google Scholar 

  15. Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M, Tsuneyoshi M. Nuclear expression of Y-box binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression and with poor prognosis in synovial sarcoma. J Pathol. 2003;199:251–8.

    Article  PubMed  CAS  Google Scholar 

  16. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Gleave ME, Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59:337–49.

    Article  PubMed  CAS  Google Scholar 

  17. Shibao K, Takano H, Nakayama Y, Okazaki K, Nagat N, Izumi H, Uchiumi T, Kuwano M, Kohno K, Itoh H. Enhanced coexpression of YB-1 and DNA topoisomerase II a genes in human colorectalcarcinomas. Int J Cancer. 1999;83:732–7.

    Article  PubMed  CAS  Google Scholar 

  18. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M, Iwamoto Y. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteocarcinoma. Clin Cancer Res. 1998;4:2273–7.

    PubMed  CAS  Google Scholar 

  19. Bergmann S, Royer-Pokora B, Fietze E, Jürchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M, Royer HD. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005;10:4078–87.

    Article  Google Scholar 

  20. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, K A, Yokomizo A, Naito S, Kohno K. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008;68:98–105.

    Article  PubMed  CAS  Google Scholar 

  21. Fujii T, Seki N, Namoto-Matsubayashi R, Takahashi H, Inoue Y, Toh U, Kage M, Shirouzu K. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008;68:8661–6.

    Article  Google Scholar 

  22. Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug. Blood. 2008;111:3714–22.

    Article  PubMed  CAS  Google Scholar 

  23. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene. 2005;24:3177–86.

    Article  PubMed  CAS  Google Scholar 

  24. Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shimoyama T, Nishio K, Kuwano M. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene. 2007;26:2736–46.

    Article  PubMed  CAS  Google Scholar 

  25. Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, Royer HD. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsicMDR1 gene expression. NatMed. 1997;3:447–50.

    Article  CAS  Google Scholar 

  26. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol. 2005;26:607–13.

    PubMed  CAS  Google Scholar 

  27. Tay WL, Yip GWC, Tan PH, Matsumoto K, Yeo R, Ng TP, Kumar SD, Tsujimoto M, Bay BH. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009;22:282–90.

    Article  PubMed  CAS  Google Scholar 

  28. McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46:4244–8.

    Google Scholar 

  29. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25:691–8.

    Article  PubMed  CAS  Google Scholar 

  30. Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins:coupling control of transcription and translation. Trends Cell Biol. 1998;8:318–23.

    Article  PubMed  CAS  Google Scholar 

  31. Evdokimova V, Ruzanov P, Imataka H, Raught B, Svitkin Y, Ovchinnikov LP, Sonenberg N. The major mRNA-associated protein YB-1 is a potent 5′ cap-dependent mRNA stabilizer. EMBO J. 2001;20:5491–502.

    Article  PubMed  CAS  Google Scholar 

  32. Skabkin MA, Kiselyova OI, Chernov KG, Sorokin AV, Dubrovin EV, Yaminsky IV, Vasiliev VD, Ovchinnikov LP. Structural organization of mRNA complexes with major core mRNP protein YB-1. Nucl Acids Res. 2004;32:5621–35.

    Article  PubMed  CAS  Google Scholar 

  33. Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003;12:35516–23.

    Article  Google Scholar 

  34. Chaudhary PM, Roninson LB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993;85:632–9.

    Article  PubMed  CAS  Google Scholar 

  35. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004;3:1485–92.

    PubMed  CAS  Google Scholar 

  36. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem. 1998;273:5997–6000.

    Article  PubMed  CAS  Google Scholar 

  37. Li Y, Wen ZS, Yang HX, Luo RZ, Zhang Y, Zhang MF, Wang X, Jia WH. High Expression of Y-Box-Binding Protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma. Ann Surg Oncol 2011 Jun 1. [Epub ahead of print].

  38. Toulany M, Schickfluß TA, Eicheler W, Kehlbach R, Schittek B, Rodemann HP. Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011;13:R28.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Mian Yang Central Hospital, Mian Yang, Sichuan, 621000, People’s Republic of China

    Y. Zhang, S. R. Reng, Z. H. Zhao, J. Wang, G. Feng, T. Z. Dai, J. Pu & X. B. Du

  2. Department of Obstetrics and Gynecology, Mian Yang Central Hospital, Mian Yang, Sichuan, People’s Republic of China

    L. Wang & L. Lu

  3. Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou, People’s Republic of China

    Z. K. Zhang, X. D. Feng & X. D. Ding

Authors
  1. Y. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. R. Reng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Z. H. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z. K. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. X. D. Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. X. D. Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T. Z. Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Pu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. X. B. Du
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. B. Du.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Y., Reng, S.R., Wang, L. et al. Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy. Med Oncol 29, 1992–1997 (2012). https://doi.org/10.1007/s12032-011-0062-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0062-2

Keywords

Search

Navigation